Sun Pharmaceutical Industries

CompanyIndiaFounded 1983

Sun Pharmaceutical Industries develops one asset, in human trials (Utreglutide in obesity). Mostly peptide acting on Insulin/IGF-1 signalling and GLP1R; based in India, founded in 1983.

1
Asset
Furthest stage: Human trials; 13
Trials: 0
Signals

Pipeline

1

Utreglutide
Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, improve glycemic control, and reduce body weight.
Human trials, Peptide, Insulin/IGF-1 signalling, GLP1R, obesity, type 2 diabetes

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials15
Signals3
Similar companies6

Papers

The effects of tildrakizumab in the epigenetic aging deviation of psoriasis: A 52-week open-label study
Journal of the American Academy of Dermatology, 19 Aug 2026
Utreglutide (GL0034) Shows Comparable Tolerability and Efficacy with Different Dose Escalation Regimens in Overweight and Obese Adults with Type 2 Diabetes (T2DM)
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Durable Cardiometabolic Effects of Utreglutide in Metabolic Dysfunction–Associated Steatotic Liver Disease Patients with Nondiabetic and Prediabetic Status
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
Comparative Efficacy and Tolerability of Incretin-Based Medication for Weight Loss in Adults with Overweight or Obesity: A Meta-Analysis of Randomized Controlled Trials
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
Effects of Once-Weekly Utreglutide (GL0034) in Individuals with Overweight and Obesity on Lipid Metabolism—A 10-Week Exploratory Proof-of-Concept Study
ADA Scientific Sessions 2025 abstract, 13 Jun 2025